RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development

Sarah A. Carratt; Garth L. Kong; Cody Coblentz; Zachary Schonrock; Lauren Maloney; Ben Weeder; Will Yashar; Rowan Callahan; Hunter Blaylock; Colin Coleman; Dan Coleman; Theodore P. Braun; Julia E. Maxson

doi:10.1038/s41375-023-01862-8

RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development

Sarah A. Carratt, Garth L. Kong, Cody Coblentz, Zachary Schonrock, Lauren Maloney, Ben Weeder, Will Yashar, Rowan Callahan, Hunter Blaylock, Colin Coleman, Dan Coleman, Theodore P. Braun, Julia E. Maxson

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1141-1146
Number of pages	6
Journal	Leukemia
Volume	37
Issue number	5
DOIs	https://doi.org/10.1038/s41375-023-01862-8
State	Published - May 2023

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-023-01862-8

Cite this

@article{f5b127fb9d7b4c37b2107b4975560cfd,

title = "RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development",

author = "Carratt, {Sarah A.} and Kong, {Garth L.} and Cody Coblentz and Zachary Schonrock and Lauren Maloney and Ben Weeder and Will Yashar and Rowan Callahan and Hunter Blaylock and Colin Coleman and Dan Coleman and Braun, {Theodore P.} and Maxson, {Julia E.}",

note = "Funding Information: Research reported in this publication was supported by NCI F32CA239422 and an OHSU SciOps award to SAC; an American Society of Hematology Research Restart Award, an American Society of Hematology Scholar Award and 1 K08 CA245224 from NCI awarded to TPB; NCI R01 CA247943, American Cancer Society RSG-19-184-01-LIB, and an LLS Scholar Award to JEM. We thank the following OHSU core facilities for their assistance: Advanced Light Microscopy, Histopathology Shared Resource, Flow Cytometry Shared Resource, ExaCloud Cluster Computational Resource, and the Advanced Computing Center. Funding Information: JEM discloses a collaboration with Ionis pharmaceuticals, research funding from Gilead Sciences, Kura Oncology and Blueprint Medicines. WY is a former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WY surrendered all of his common stock options in March 2021. The other authors do not have conflicts of interest, financial or otherwise. Funding Information: Research reported in this publication was supported by NCI F32CA239422 and an OHSU SciOps award to SAC; an American Society of Hematology Research Restart Award, an American Society of Hematology Scholar Award and 1 K08 CA245224 from NCI awarded to TPB; NCI R01 CA247943, American Cancer Society RSG-19-184-01-LIB, and an LLS Scholar Award to JEM. We thank the following OHSU core facilities for their assistance: Advanced Light Microscopy, Histopathology Shared Resource, Flow Cytometry Shared Resource, ExaCloud Cluster Computational Resource, and the Advanced Computing Center.",

year = "2023",

month = may,

doi = "10.1038/s41375-023-01862-8",

language = "English (US)",

volume = "37",

pages = "1141--1146",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development

AU - Carratt, Sarah A.

AU - Kong, Garth L.

AU - Coblentz, Cody

AU - Schonrock, Zachary

AU - Maloney, Lauren

AU - Weeder, Ben

AU - Yashar, Will

AU - Callahan, Rowan

AU - Blaylock, Hunter

AU - Coleman, Colin

AU - Coleman, Dan

AU - Braun, Theodore P.

AU - Maxson, Julia E.

N1 - Funding Information: Research reported in this publication was supported by NCI F32CA239422 and an OHSU SciOps award to SAC; an American Society of Hematology Research Restart Award, an American Society of Hematology Scholar Award and 1 K08 CA245224 from NCI awarded to TPB; NCI R01 CA247943, American Cancer Society RSG-19-184-01-LIB, and an LLS Scholar Award to JEM. We thank the following OHSU core facilities for their assistance: Advanced Light Microscopy, Histopathology Shared Resource, Flow Cytometry Shared Resource, ExaCloud Cluster Computational Resource, and the Advanced Computing Center. Funding Information: JEM discloses a collaboration with Ionis pharmaceuticals, research funding from Gilead Sciences, Kura Oncology and Blueprint Medicines. WY is a former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WY surrendered all of his common stock options in March 2021. The other authors do not have conflicts of interest, financial or otherwise. Funding Information: Research reported in this publication was supported by NCI F32CA239422 and an OHSU SciOps award to SAC; an American Society of Hematology Research Restart Award, an American Society of Hematology Scholar Award and 1 K08 CA245224 from NCI awarded to TPB; NCI R01 CA247943, American Cancer Society RSG-19-184-01-LIB, and an LLS Scholar Award to JEM. We thank the following OHSU core facilities for their assistance: Advanced Light Microscopy, Histopathology Shared Resource, Flow Cytometry Shared Resource, ExaCloud Cluster Computational Resource, and the Advanced Computing Center.

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85149481458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149481458&partnerID=8YFLogxK

U2 - 10.1038/s41375-023-01862-8

DO - 10.1038/s41375-023-01862-8

M3 - Article

C2 - 36894620

AN - SCOPUS:85149481458

SN - 0887-6924

VL - 37

SP - 1141

EP - 1146

JO - Leukemia

JF - Leukemia

IS - 5

ER -

RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this